-
1
المؤلفون: Paul Monagle, Anthonie W A Lensing, Kirstin Thelen, Ida Martinelli, Christoph Male, Amparo Santamaría, Elena Samochatova, Riten Kumar, Susanne Holzhauer, Paola Saracco, Paolo Simioni, Jeremy Robertson, Gernot Grangl, Jacqueline Halton, Phillip Connor, Guy Young, Angelo C Molinari, Ulrike Nowak-Göttl, Gili Kenet, Stefanie Kapsa, Stefan Willmann, Akos F Pap, Michael Becka, Teresa Twomey, Jan Beyer-Westendorf, Martin H Prins, Dagmar Kubitza, Werner Streif, Jorge Carniero, Sandra Logetto, Leonardo Brandao, Pascal Amedro, Damien Bonnet, Sven Dietrich, Krisztian Kallay, Shoshana Revel-Vilk, Hannah Tamary, Paola Giordano, Maria Abbattista, Andrea Artoni, Daniela Tormene, Hiroshi Ono, Maroeska WM Te Loo, Heleen Van Ommen, Margreet A Veening, Monique H Suiker, Marjolein Peters, Anastasia Shamardina, Nizhny Novgorod, Lyudmila Zubarovskaya, Maria A Dasi, Maria Elorza, Amparo Santamaria, Manuel Sánchez-Luna, Manuela Albisetti, Sebastian Grunt, Kaan Kavakli, Tina Biss, Philip Connor, Mike Williams, Suchitra Acharya, Rumi Bhat, Susan Kearney, Kavita Patel, Madvi Rajpukar, Jeffrey H Schwartz, Terry Vik, Tung Wynn, Donald L Yee
المساهمون: MUMC+: KIO Kemta (9), Epidemiologie, RS: CAPHRI - R5 - Optimising Patient Care, Pediatric surgery
المصدر: The Lancet Haematology, 6(10), E500-E509. ELSEVIER SCI LTD
Lancet Haematology
r-FISABIO. Repositorio Institucional de Producción Científica
instname
The Lancet Haematology, 6(10), e500-e509. Lancet Publishing Group
Monagle, P, Lensing, A W A, Thelen, K, Martinelli, I, Male, C, Santamaría, A, Samochatova, E, Kumar, R, Holzhauer, S, Saracco, P, Simioni, P, Robertson, J, Grangl, G, Halton, J, Connor, P, Young, G, Molinari, A C, Nowak-Göttl, U, Kenet, G, Kapsa, S, Willmann, S, Pap, A F, Becka, M, Twomey, T, Beyer-Westendorf, J, Prins, M H, Kubitza, D & EINSTEIN-Jr Phase 2 Investigators 2019, ' Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies ', The Lancet Haematology, vol. 6, no. 10, pp. e500-e509 . https://doi.org/10.1016/S2352-3026(19)30161-9مصطلحات موضوعية: Male, Pediatrics, Fondaparinux, 0302 clinical medicine, Rivaroxaban, Drug Dosage Calculations, DEEP-VEIN THROMBOSIS, Young adult, Adolescent, Anemia, Anticoagulants, Body Weight, Child, Child, Preschool, Drug Administration Schedule, Factor Xa, Female, Half-Life, Hemorrhage, Humans, Infant, Neutropenia, Prothrombin Time, Treatment Outcome, Venous Thromboembolism, Hematology, Vitamin K antagonist, REPORTED TREATMENT SATISFACTION, ORAL RIVAROXABAN, 030220 oncology & carcinogenesis, medicine.symptom, medicine.drug, medicine.medical_specialty, medicine.drug_class, Asymptomatic, 03 medical and health sciences, medicine, Dosing, Preschool, business.industry, medicine.disease, XA INHIBITOR RIVAROXABAN, Clinical trial, DEFINITION, ATRIAL-FIBRILLATION, business, STANDARD THERAPY, 030215 immunology